Biomerica (BMRA) Asset Writedowns and Impairment (2011 - 2026)

Biomerica has disclosed Asset Writedowns and Impairment across 16 years of filings, most recently posting -$59000.0 for Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at -$59000.0, down 5800.0% year-over-year; the trailing twelve-month figure through Feb 2026 was $12000.0 (up 300.0% YoY), and the FY2025 annual result was $8000.0, up 180.0% from the prior year.
• Asset Writedowns and Impairment came in at -$59000.0 for Q1 2026 at Biomerica, down from $32000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $478000.0 in Q2 2023 to a low of -$505000.0 in Q1 2023.
• The 5-year median for Asset Writedowns and Impairment is $1000.0 (2024), against an average of $32242.5.
• Across the five-year window, Asset Writedowns and Impairment slumped 6647.73% in 2023 and surged 900.0% in 2025, its largest moves.
• Biomerica's Asset Writedowns and Impairment stood at $139000.0 in 2022, then jumped by 243.88% to $478000.0 in 2023, then plunged by 100.84% to -$4000.0 in 2024, then soared by 900.0% to $32000.0 in 2025, then tumbled by 284.38% to -$59000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at -$59000.0 (Q1 2026), $32000.0 (Q4 2025), and $38000.0 (Q3 2025), per Business Quant data.